The Journal of Immunology, Vol 137, Issue 4 1329-1335, Copyright © 1986 by American Association of Immunologists

ARTICLES

The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing

VL Tesh, RL Duncan Jr and DC Morrison

We have examined the killing of E. coli and kinetics of lipopolysaccharide (LPS) release after the exposure of the bacteria to normal human serum (NHS) and sera deficient in complement components, or with inactivated complement components. LPS of the galactose epimerase-deficient strain E. coli J5 were specifically radiolabeled by growing the bacteria in a medium containing [3H]galactose. Exposure of the washed bacteria to NHS resulted in a significant reduction (greater than 99%) in viability within 15 min and the concomitant release of radiolabeled LPS. However, maximal release of LPS was consistently 30% of the total radiolabel incorporated into the LPS molecules. The amount of tritium-labeled LPS released was shown to be directly proportional to the concentration of bacteria exposed to NHS, suggesting that release of LPS was not limited by the availability of some critical serum component(s). The consumption of complement in NHS by incubation with E. coli was demonstrated by decreased alternative and classical pathway-specific hemolytic activity. The use of Factor D-depleted and VEM-treated human sera demonstrated that, with these bacteria, both the alternative and classical pathways of complement contribute to bacterial killing and release of LPS. It is noteworthy that, in VEM- treated and Factor D-depleted sera, the rate of killing and the kinetics of LPS release were somewhat slower as compared to control serum. Bacterial killing in C7-depleted and C9-deficient human sera was minimal. Neither killing nor LPS release occurred in heat-inactivated (56 degrees C, 30 min) human serum. The amount of [3H]LPS released by C9-deficient serum was qualitatively similar to the amount released by the action of NHS. Tritium-labeled LPS was not released in C7-depleted serum. These data indicate that bacterial killing can be dissociated from LPS release, and suggest that, whereas LPS release may be necessary for the bactericidal effects of serum complement, it is probably not sufficient to effect killing. Furthermore, a significant fraction of LPS can be removed from the outer membrane of the bacteria without an apparent affect on viability.

This article has been cited by other articles:

				W. Jia, A. E. Zoeiby, T. N. Petruzziello, B. Jayabalasingham, S. Seyedirashti, and R. E. Bishop Lipid Trafficking Controls Endotoxin Acylation in Outer Membranes of Escherichia coli J. Biol. Chem., October 22, 2004; 279(43): 44966 - 44975. [Abstract] [Full Text] [PDF]

				R. L. Kitchens, P. A. Thompson, G. E. O'Keefe, and R. S. Munford Plasma constituents regulate LPS binding to, and release from, the monocyte cell surface Innate Immunity, December 1, 2000; 6(6): 477 - 482. [Abstract] [PDF]

				J. Hellman, P. M. Loiselle, M. M. Tehan, J. E. Allaire, L. A. Boyle, J. T. Kurnick, D. M. Andrews, K. Sik Kim, and H. S. Warren Outer Membrane Protein A, Peptidoglycan-Associated Lipoprotein, and Murein Lipoprotein Are Released by Escherichia coli Bacteria into Serum Infect. Immun., May 1, 2000; 68(5): 2566 - 2572. [Abstract] [Full Text] [PDF]

				S. S. Katz, Y. Weinrauch, R. S. Munford, P. Elsbach, and J. Weiss Deacylation of Lipopolysaccharide in Whole Escherichia coli during Destruction by Cellular and Extracellular Components of a Rabbit Peritoneal Inflammatory Exudate J. Biol. Chem., December 17, 1999; 274(51): 36579 - 36584. [Abstract] [Full Text] [PDF]

				P. van Langevelde, K. M. C. Kwappenberg, P. H. P. Groeneveld, H. Mattie, and J. T. van Dissel Antibiotic-Induced Lipopolysaccharide (LPS) Release from Salmonella typhi: Delay between Killing by Ceftazidime and Imipenem and Release of LPS Antimicrob. Agents Chemother., April 1, 1998; 42(4): 739 - 743. [Abstract] [Full Text]

				K. C. Lamp and M. K. Vickers Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro Infection Model against Escherichia coli Strains with Various Levels of Resistance Antimicrob. Agents Chemother., February 1, 1998; 42(2): 231 - 235. [Abstract] [Full Text]